The DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Regulation and Function of the PD-L1 Checkpoint
Open accessAbstract
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immunity by counteracting T cell-activating signals. Antibody-based PD-1-PD-L1 inhibitors can induce durable tumor remissions in patients with diverse advanced cancers, and thus expression of PD-L1 on tumor cells and other cells in the tumor microenviroment is of major clinical relevance. Here we review the roles of the PD-1-PD-L1 axis in cancer, focusing on recent findings on the mechanisms that regulate PD-L1 expression at the transcriptional, posttranscriptional, and protein level. We place this knowledge in the context of observations in the clinic and discuss how it may inform the design of more precise and effective cancer immune checkpoint therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cited by
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Tang, R., Xu, J., Zhang, B., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00946-7 · Cited by 1,273
Mechanisms Controlling PD-L1 Expression in Cancer
Cha, J.-H., Chan, L.-C., Li, C.-W., Hsu, J. L., & Hung, M.-C. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,045
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
The CD47-SIRPα Immune Checkpoint
Logtenberg, M. E. W., Scheeren, F. A., & Schumacher, T. N. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.011 · Cited by 735
Self-citationImmune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akinleye, A., & Rasool, Z. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0779-5 · Cited by 733
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
“The PD-1/PD-L1 pathway restrains the hyperactivation of immune cells and prevents autoimmune diseases [3].”
BackgroundCXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers
Bill, R., Wirapati, P., Messemaker, M., Roh, W., Zitti, B., Duval, F., Kiss, M., Park, J. C., Saal, T. M., Hoelzl, J., et al. (2023) · Science · doi:10.1126/science.ade2292 · Cited by 663
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Twomey, J. D., & Zhang, B. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00574-0 · Cited by 657
Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18570-x · Cited by 553
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Shen, X., & Zhao, B. (2018) · BMJ · doi:10.1136/bmj.k3529 · Cited by 559
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis
Carvelli, J., Demaria, O., Vély, F., Batista, L., Chouaki Benmansour, N., Fares, J., Carpentier, S., Thibult, M.-L., Morel, A., Remark, R., et al. (2020) · Nature · doi:10.1038/s41586-020-2600-6 · Cited by 526
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Wu, Q., You, L., Nepovimova, E., Heger, Z., Wu, W., Kuca, K., & Adam, V. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01292-6 · Cited by 485
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 477
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 469
LAG-3: from molecular functions to clinical applications
Maruhashi, T., Sugiura, D., Okazaki, I.-M., & Okazaki, T. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001014 · Cited by 459
Sung, Y.-C., Jin, P.-R., Chu, L.-A., Hsu, F.-F., Wang, M.-R., Chang, C.-C., Chiou, S.-J., Qiu, J. T., Gao, D.-Y., Lin, C.-C., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0570-3 · Cited by 452
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
E3 ubiquitin ligases: styles, structures and functions
Yang, Q., Zhao, J., Chen, D., & Wang, Y. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00043-2 · Cited by 435
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
Ruscetti, M., Morris, J. P., Mezzadra, R., Russell, J., Leibold, J., Romesser, P. B., Simon, J., Kulick, A., Ho, Y.-J., Fennell, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.008 · Cited by 424
Self-citationZhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Wu, Q., Jiang, L., Li, S.-C., He, Q.-J., Yang, B., & Cao, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0366-x · Cited by 414
Immunosuppressive Mechanisms of Regulatory B Cells
Catalán, D., Mansilla, M. A., Ferrier, A., Soto, L., Oleinika, K., Aguillón, J. C., & Aravena, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611795 · Cited by 399
Sugiura, D., Maruhashi, T., Okazaki, I.-M., Shimizu, K., Maeda, T. K., Takemoto, T., & Okazaki, T. (2019) · Science · doi:10.1126/science.aav7062 · Cited by 386
Regulation of PD-L1 Expression by NF-κB in Cancer
Antonangeli, F., Natalini, A., Garassino, M. C., Sica, A., Santoni, A., & Di Rosa, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584626 · Cited by 385
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Qin, W., Hu, L., Zhang, X., Jiang, S., Li, J., Zhang, Z., & Wang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02298 · Cited by 369
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Park, L. M., Lannigan, J., & Jaimes, M. C. (2020) · Cytometry Part A · doi:10.1002/cyto.a.24213 · Cited by 350
“The inhibitory receptor PD-1 is crucial for the regulation of immune responses and to avoid excessive immune activation (53).”
Backgroundp53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
Targeting CD47 for cancer immunotherapy
Jiang, Z., Sun, H., Yu, J., Tian, W., & Song, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01197-w · Cited by 346
Understanding the tumor microenvironment for effective immunotherapy
Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 337
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models
Allen, B. M., Hiam, K. J., Burnett, C. E., Venida, A., DeBarge, R., Tenvooren, I., Marquez, D. M., Cho, N. W., Carmi, Y., & Spitzer, M. H. (2020) · Nature Medicine · doi:10.1038/s41591-020-0892-6 · Cited by 328
Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy
Xie, F., Zhou, X., Fang, M., Li, H., Su, P., Tu, Y., Zhang, L., & Zhou, F. (2019) · Advanced Science · doi:10.1002/advs.201901779 · Cited by 327
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Rodriguez-Garcia, A., Palazon, A., Noguera-Ortega, E., Powell, D. J., & Guedan, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01109 · Cited by 312
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
Hsu, J.-M., Li, C.-W., Lai, Y.-J., & Hung, M.-C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1892 · Cited by 286
Palmitoylation stabilizes PD-L1 to promote breast tumor growth
Yang, Y., Hsu, J.-M., Sun, L., Chan, L.-C., Li, C.-W., Hsu, J. L., Wei, Y., Xia, W., Hou, J., Qiu, Y., et al. (2019) · Cell Research · doi:10.1038/s41422-018-0124-5 · Cited by 278
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
Schönrich, G., & Raftery, M. J. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00207 · Cited by 275
Yang, Z., Gao, D., Guo, X., Jin, L., Zheng, J., Wang, Y., Chen, S., Zheng, X., Zeng, L., Guo, M., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c07721 · Cited by 275
Emerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 275
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint
Tang, T., Cheng, X., Truong, B., Sun, L., Yang, X., & Wang, H. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107709 · Cited by 271
H3K18 Lactylation Potentiates Immune Escape of Non–Small Cell Lung Cancer
Zhang, C., Zhou, L., Zhang, M., Du, Y., Li, C., Ren, H., & Zheng, L. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3513 · Cited by 264
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
Qu, J., Yan, H., Hou, Y., Cao, W., Liu, Y., Zhang, E., He, J., & Cai, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01224-4 · Cited by 260
Pang, K., Shi, Z.-D., Wei, L.-Y., Dong, Y., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J.-J., Chen, Y.-A., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100907 · Cited by 260
Liu, C., Liu, R., Wang, B., Lian, J., Yao, Y., Sun, H., Zhang, C., Fang, L., Guan, X., Shi, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001895 · Cited by 257
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Wang, Y., Zhang, H., Liu, C., Wang, Z., Wu, W., Zhang, N., Zhang, L., Hu, J., Luo, P., Zhang, J., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01325-0 · Cited by 257
Fang, W., Zhou, T., Shi, H., Yao, M., Zhang, D., Qian, H., Zeng, Q., Wang, Y., Jin, F., Chai, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01786-6 · Cited by 256
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 256
Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01045-x · Cited by 233
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Xu, L., Zhang, Y., Tian, K., Chen, X., Zhang, R., Mu, X., Wu, Y., Wang, D., Wang, S., Liu, F., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0929-6 · Cited by 177
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
Thiem, A., Hesbacher, S., Kneitz, H., di Primio, T., Heppt, M. V., Hermanns, H. M., Goebeler, M., Meierjohann, S., Houben, R., & Schrama, D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1403-9 · Cited by 153
Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
Deng, S., Hu, Q., Zhang, H., Yang, F., Peng, C., & Huang, C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1068 · Cited by 116
Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome
Fakih, M., Ouyang, C., Wang, C., Tu, T. Y., Gozo, M. C., Cho, M., Sy, M., Longmate, J. A., & Lee, P. P. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127046 · Cited by 84
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
Metabolic reprogramming in tumors: Contributions of the tumor microenvironment
Lane, A. N., Higashi, R. M., & Fan, T. W.-M. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2019.10.007 · Cited by 91
Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer
Sivaram, N., McLaughlin, P. A., Han, H. V., Petrenko, O., Jiang, Y.-P., Ballou, L. M., Pham, K., Liu, C., van der Velden, A. W. M., & Lin, R. Z. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123540 · Cited by 78
Liu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00816-w · Cited by 75
Chen, X., Zhao, J., Yue, S., Li, Z., Duan, X., Lin, Y., Yang, Y., He, J., Gao, L., Pan, Z., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00760-x · Cited by 68
PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation
Shimizu, K., Sugiura, D., Okazaki, I.-M., Maruhashi, T., Takegami, Y., Cheng, C., Ozaki, S., & Okazaki, T. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.012 · Cited by 63
Genomics and the Immune Landscape of Osteosarcoma
Wu, C.-C., & Livingston, J. A. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43085-6_2 · Cited by 58
cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer
Kabashima, A., Matsuo, Y., Ito, S., Akiyama, Y., Ishii, T., Shimada, S., Masamune, A., Tanabe, M., & Tanaka, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-14297-5 · Cited by 55
Wang, Q., Bardhan, K., Boussiotis, V. A., & Patsoukis, N. (2021) · Advanced Biology · doi:10.1002/adbi.202100758 · Cited by 39
Enzyme/pH Dual-Responsive Engineered Nanoparticles for Improved Tumor Immuno-Chemotherapy
Liu, Z., Hao, X., Qian, J., Zhang, H., Bao, H., Yang, Q., Gu, W., Huang, X., & Zhang, Y. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c18348 · Cited by 24
Rolles, B., Gorgulho, J., Tometten, M., Roderburg, C., Vieri, M., Abels, A., Vucur, M., Heymann, F., Tacke, F., Brümmendorf, T. H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.729207 · Cited by 12
Metadata
- Authors
- Sun, C., Mezzadra, R., & Schumacher, T. N.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 48
- Issue
- 3
- Pages
- 434-452
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2790574591
- Cited by
- 2,193
- References
- 231
- FWCI
- 62.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.